A new stemcell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.
A sugar gel called 2-deoxy-D-ribose (2dDR) shows potential for promoting hair regrowth by increasing blood supply to hair follicles, similar to Minoxidil, but its effectiveness in humans is unproven. It may benefit those who don't tolerate Minoxidil, but it is not a replacement for treatments like Finasteride or RU58841.
Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.
A mixture of MSM, kombucha, and black tea was applied topically for hair growth in mice. The conversation suggests skepticism about translating these results to humans.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stemcell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
A recent publication suggests that the flavonoids eriocitrin and silymarin may be more effective than finasteride in binding to the enzyme responsible for hair loss. People in the conversation are skeptical about the effectiveness and safety of these flavonoids until tested on humans, and some discuss their personal experiences with other treatments.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.
The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.
After a hair transplant, it's advised to stop using RU58841 and minoxidil to avoid irritation, resuming them 25-30 days post-surgery if the scalp is healed. The user is currently using finasteride, minoxidil, and RU58841, but there are concerns about the safety and efficacy of RU58841 in humans.
Adipose fat cells and stemcells may help treat hair loss by restoring the scalp's thickness. Treatments like NanoFat injections and Botox are discussed for their potential to promote hair growth.
Adipose-derived stemcell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.
Stemcell hair transplants use stemcells from fat tissue to reactivate inactive hair follicles, but results are inconsistent and not widely shared. Traditional treatments like finasteride and minoxidil often show better results.
A new hair growth product claims to use apple stemcells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.
Hair follicle stemcells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Stemcell therapy shows promise in treating hair loss by mimicking DHT-resistant cells from the back of the head. Traditional treatments like finasteride are also discussed, but stemcells could potentially offer a more permanent solution.
.
This conversation discussed the efficacy of Minoxidil and Finasteride as treatments for hair loss, with a focus on the potential side effects of taking Oral Minoxidil. Some users shared their experiences with both treatments and there was debate over whether they were safe or not.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
PP405 shows promise in hair loss treatment, but stemcell therapy using adipose-derived stemcells and ATP also successfully reversed androgenetic alopecia in mice. Stemcell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
A user proposed genetically engineering scalp stemcells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
Baldness is not an evolutionary disadvantage because it occurs after reproductive age. Treatments like Minoxidil and Finasteride are used for androgenetic alopecia but don't address the root cause.
Dutasteride may be better for the brain than Finasteride, potentially increasing dopamine levels and causing fewer side effects. For those switching from Finasteride to Dutasteride to prevent hair loss, it's recommended to continue Finasteride for 3-4 months while starting Dutasteride to avoid shedding due to Dutasteride's long half-life.
A US federal judge ruled that using patients' stemcells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stemcell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
The conversation discusses hair loss treatments, specifically Regenera stemcells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
There is concern about a potential ban on finasteride and dutasteride in the EU, with users discussing the impact on hair loss treatment. Some suggest alternative treatments or express skepticism about the likelihood of a ban.
There is concern about a potential ban on finasteride in the EU, but many believe it is unlikely unless serious side effects are found. Users rely on finasteride for hair loss and other health benefits, and a petition has been created to oppose any restrictions.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.